96013-78-4

Upstream product

• 620-24-6 3-Hydroxybenzyl alcohol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 41879-37-2 t-butyldimethylsilyl amine 
• 96013-69-3 tert-butyl((3-((tert-butyldimethylsilyl)oxy)benzyl)oxy)dimethylsilane 

Downstream Products

• 654069-08-6 3-({[tert-butyl(dimethyl)silyl]oxy}methyl)phenyl(2Z)-4-hydroxy-2-[4-(methylsulfonyl)phenyl]-3-phenylbut-2-enyl carbonate 
• 53172-91-1 (benzyloxy)(tert-butyl)dimethylsilane 
• 1100767-49-4 1-{3-bromo-4-[3-(tert-butyl-dimethyl-silanyloxymethyl)-phenoxy]-phenyl}-ethanone 

Relevant academic research and scientific papers

Toward the Total Synthesis of Scabrosins: Synthesis of a Desulfur-scabrosin Skeleton and Its Stereoisomers

The enantioselective synthesis of a desulfur-scabrosin skeleton was reported. The synthesis began from 3-(hydroxymethyl)phenol, and key steps include asymmetric nucleophilic epoxidation, a Mitsunobu reaction using a sulfonamide as the nucleophile, the con

Synthesis method of Scabrosins/Ambewelamides skeleton structure

The invention relates to a synthesis method of a Scabrosins/Ambewelamides skeleton structure. According to the synthesis method, a Negishi coupling reaction, a reductive amination reaction, an asymmetric epoxidation reaction, a Mitsunobu reaction and an i

TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE

The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

Conformational Constraint of the Glycerol Moiety of Lysophosphatidylserine Affords Compounds with Receptor Subtype Selectivity

Lysophosphatidylserine (LysoPS) is an endogenous lipid mediator that specifically activates membrane proteins of the P2Y and its related families of G protein-coupled receptors (GPCR), GPR34 (LPS1), P2Y10 (LPS2), and GPR174 (LPS3). Here, in order to increase potency and receptor selectivity, we designed and synthesized LysoPS analogues containing the conformational constraints of the glycerol moiety. These reduced structural flexibility by fixation of the glycerol framework of LysoPS using a 2-hydroxymethyl-3-hydroxytetrahydropyran skeleton, and related structures identified compounds which exhibited high potency and selectivity for activation of GPR34 or P2Y10. Morphing of the structural shape of the 2-hydroxymethyl-3-hydroxytetrahydropyran skeleton into a planar benzene ring enhanced the P2Y10 activation potentcy rather than the GPR34 activation.

LYSOPHOSPHATIDYLSERINE DERIVATIVE

PROBLEM TO BE SOLVED: To provide a lysophosphatidylserine derivative or salt thereof. SOLUTION: The present invention provides a lysophosphatidylserine derivative or salt thereof, or a pharmaceutical composition or lysophosphatidylserine receptor function modulator including the compound or salt thereof. SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

Tert-Butyldimethylsilyl Amine (TBDMS-NH2): A Mild and Green Reagent for the Protection of Benzyl Alcohols, Phenols, and Carboxylic Acids under Solvent-Free Conditions

Herein, we present the use of the tert-butyldimethylsilyl amine (TBDMS-NH2) as a silylating reagent for phenols, benzyl alcohols, and carboxylic acids. Unlike other silyl protection reactions, this reported process with TBDMS-NH2 does not involve the form

MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY

The present invention relates to compounds of the formula (I). The compounds of the formula (I) are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are inhibitors of the blood clotting enzymes, especially factor VIla and can in general be applied in conditions in which an undesired activity of factor VIla is present or for the cure or prevention of which an inhibition of factor VIla is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

DBU-mediated mild and chemoselective deprotection of aryl silyl ethers and tandem biaryl ether formation

An efficient method for the selective cleavage of aryl silyl ethers is established using 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). With either 1.0 or 0.10 equivalent of DBU, smooth desilylation of various aryl silyl ethers was accomplished selectively in the presence of alkyl silyl ethers and other base-sensitive groups such as acetate and ester. In addition, direct transformation of aryl silyl ethers into biaryl ethers using a catalytic amount of DBU was possible through tandem desilylation and SNAr reaction with activated aryl fluorides. Georg Thieme Verlag Stuttgart.

NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS

The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions

Selective deprotection of either alkyl or aryl silyl ethers from aryl, alkyl bis-silyl ethers

A pair of complementary methods was developed using CeCl3·7H2O/CH3CN and LiOH/DMF to selectively deprotect alkyl and aryl silyl ethers, respectively, from the corresponding bis-silyl ethers in excellent yields.